February 22, 2021August 24, 2022
Enhertu Approved in UK for Inoperable, Advanced Breast Cancer
News
Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic ... Read more
February 18, 2021February 18, 2021
Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC
News
An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in ... Read more
February 15, 2021February 15, 2021
Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer
News
Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously ... Read more
February 11, 2021February 11, 2021
Trial Testing AL101 in TNBC Doses First Patient
News
The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy ... Read more
February 8, 2021February 8, 2021
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer
News
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative ... Read more
February 4, 2021February 4, 2021
Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors
News
Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide ... Read more
February 1, 2021February 1, 2021
US Study Enrolling Women to Help Determine Best Screening Practices
News
A national study is seeking women in the U.S. to help determine the safest and best way to screen for ... Read more
January 28, 2021January 28, 2021
Nonprofit Highlights Importance of Global Teamwork for World Cancer Day
News
In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation ... Read more
January 25, 2021January 25, 2021
Enhertu Approved in EU for Inoperable, Advanced Breast Cancer
News
The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer ... Read more
January 21, 2021January 21, 2021
Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA
News
Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and ... Read more
January 18, 2021January 18, 2021
Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors
News
Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The ... Read more
January 14, 2021January 14, 2021
Genetic Test for Advanced Breast Cancer Launched in EU
News
Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic ... Read more

June 28, 2019

Breast Cancer Index Identifies Patients Who Will Benefit From Extended Endocrine Therapy, Data Shows

News

Biotheranostics‘ Breast Cancer Index can help distinguish which breast cancer patients will derive a benefit from prolonged endocrine therapy — allowing those who don’t to stop treatment and avoid its ... Read more

June 26, 2019

European Commission Approves Talzenna to Treat Some Breast Cancers

News

The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy ... Read more

June 24, 2019June 27, 2019

Tecentriq-Abraxane Combo Prolonging Survival in TNBC Patients, Phase 3 Trial Data Show

News

Tecentriq in combination with Abraxane, a chemotherapy, continues to prolong overall survival in adults with triple-negative breast cancer (TNBC) who test positive for the PD-L1 factor, a new interim analysis from ... Read more

June 21, 2019

Anti-Diarrheal Medicines Improve Tolerability of Nerlynx in Breast Cancer Patients

News

Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide (brand ... Read more

June 19, 2019

Kisqali-Endocrine Therapy Combo Increases Overall Survival In Hormone Receptor-Positive Breast Cancer Patients, Study Shows

News

A combination of endocrine therapy and the targeted therapy Kisqali (ribociclib) is more effective than endocrine therapy alone at prolonging the survival of premenopausal women who have metastatic hormone receptor-positive ... Read more

June 17, 2019

FDA Approves Herceptin Biosimilar Kanjinti for HER2-positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Amgen and Allergan’s Kanjinti (trastuzumab-anns), a biosimilar to Genentech’s Herceptin (trastuzumab), for all indications of its reference product — including as a treatment ... Read more

June 14, 2019

Susan G. Komen, Cancer Australia to Co-fund Metastatic BC Research

News

A new partnership between Susan G. Komen and Cancer Australia will grant a researcher $450,000 over three years to study metastatic breast cancer. Through a Career Catalyst Research Grant provided ... Read more

June 12, 2019

Combining 2 Assessments of Breast Cancer Recurrence Risk May Help Guide Use of Adjuvant Chemotherapy

News

Adding an assessment of a woman’s clinical risk to Genomic Health‘s genomic test Oncotype DX to estimate the likelihood of breast cancer recurrence may spare more young women from having ... Read more

June 11, 2019June 7, 2019

How a $100 Bill Brings Me Peace of Mind

A Lump in the Road - A Column by Nancy Brier, Columns

I could smell cleanliness when I opened my front door. Lemon. Pine. The glorious absence of dust. It’s that elusive moment right after my housecleaners leave and my home looks ... Read more

June 7, 2019

Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer

News

End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech‘s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the ... Read more

June 5, 2019

New AI-based Model Outperforms Current Methods of Predicting Breast Cancer Risk

News

Scientists have created a new artificial intelligence (AI)-based model that outperforms current models at predicting the risks a woman has of developing breast cancer, and works equally well in white ... Read more

June 3, 2019

Chemo Resistance in TNBC Due to Molecular Changes That May Be Treatable, Study Suggests

News

Triple-negative breast cancer (TNBC) cells can become resistant to chemotherapy by temporarily turning on molecular pathways that protect the tumor, new research using mouse models and patient tumor samples uncovered. ... Read more

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

Trial Testing AL101 in TNBC Doses First Patient

‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors

US Study Enrolling Women to Help Determine Best Screening Practices

Nonprofit Highlights Importance of Global Teamwork for World Cancer Day

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Genetic Test for Advanced Breast Cancer Launched in EU